NOVATO, Calif., March 30, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced that it submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") seeking approval to market its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules (RP103), for the potential treatment of nephropathic cystinosis. In its application, Raptor has requested Priority Review of the NDA, which, if granted, could lead to a decision for marketing approval from the FDA of RP103 for the potential treatment of nephropathic cystinosis in the fourth calendar quarter of 2012. Earlier this week, on March 26, Raptor announced European Medicines Agency ("EMA") validation of its Marketing Authorization Application ("MAA") for RP103 for the potential treatment of nephropathic cystinosis.